3 results
This trial will determine the relative incidence of CV outcomes compared to placebo forthe TZD class as a whole, rosiglitazone (RSG), and pioglitazone (PIO) when added to thetherapeutic regimen of a person with type 2 diabetes who has additional…
The primary objective of this study is to evaluate the effects of SYR-322 and SYR-322coadministered with pioglitazone HC1 versus placebo on postprandial triglycerides in subjectswith type 2 diabetes.
To assess the effect of prehospital administration of crushed tablets of prasugrel loading dose (in addition to ASA and standard care) on safety and efficacy in patients treated with primary PCI for acute STEMI with last-generation DES (Firehawk*,…